| Date | Form | Description | Docs | XBRL | Pages |
| 09/12/19 | DEF 14A | Definitive proxy statements |
|
46 | |
| 09/06/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
84 |
| 08/27/19 | 8-K | Current report filing |
|
13 | |
| 08/21/19 | 8-K | Current report filing |
|
25 | |
| 07/18/19 | 8-K | Current report filing |
|
4 | |
| 06/21/19 | EFFECT | Notice of Effectiveness |
|
1 | |
| 06/19/19 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 06/18/19 | UPLOAD | SEC-generated letter |
|
1 | |
| 06/12/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
39 |
| 06/11/19 | S-3 | Registration statement for specified transactions by certain issuers |
|
137 |
Latest News & Events
Anixa Biosciences Congratulates Scientific Advisory Board Member Dr. H. Michael Shepard as a 2019 Lasker Award Honoree
Read More...Anixa Biosciences to Present at Two Upcoming Investor Conferences
Read More...Anixa Biosciences Announces VA North Texas Health Care System to Join Cchek™ Prostate Cancer Study
Read More...Cancer Fact: Approximately 30% of cancers are caused by tobacco.